NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
NewsRx | Free Newsletters
 
----------
------------
NewsRx on Facebook
-----
NewsRx Passes
Press Release Submissions
PR Login
-----
2008 Award Logo
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
-----
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.

Security by Verisign

Echinococcosis


Return to Library

Free Echinococcosis Articles


Investigators at University of Wurzburg target echinococcosis



2009 JUN 30 - (NewsRx.com) -- According to a study from Wurzburg, Germany, "We compared four enzyme-linked immunosorbent assays (ELISAs) with 172 serum samples from 28 patients with alveolar echinococcosis in different clinical stages according to the World Health Organization-PNM (P = parasitic mass in the liver, N = involvement of neighboring organs, M = metastasis) staging system. The sequential antibody responses against Em(2plus), Em10, and Em18 antigens, and a crude antigen extract were measured in cohorts with resected and unresected lesions."

"Antibody levels in all assays correlated with the PNM stage before treatment, and the highest correlation was shown for the Em18 assay. The PNM stage did not influence the antibody kinetics, but changes in antibody levels depended on the treatment. In patients after curative surgery, seroreversion in the Em(2plus) ELISA indicated successful resection of lesions in more patients than any other assay., irrespective of the clinical stage. There were no significant differences in the time before assays that use recombinant or purified antigens became unreactive," wrote D. Tappe and colleagues, University of Wurzburg.

The researchers concluded: "Antibodies directed against crude antigens were detectable longer than other antibodies in all patient cohorts and stages."

Tappe and colleagues published the results of their research in American Journal of Tropical Medicine and Hygiene (Close Relationship between Clinical Regression and Specific Serology in the Follow-up of Patients with Alveolar Echinococcosis in Different Clinical Stages. American Journal of Tropical Medicine and Hygiene, 2009;80(5):792-797).

For additional information, contact D. Tappe, University of Wurzburg, Institute Hyg & Microbiology, Josef Schneider Str 2, D-97080 Wurzburg, Germany.

The publisher of the American Journal of Tropical Medicine and Hygiene can be contacted at: American Society Trop Med & Hygiene, 8000 Westpark Dr., Ste. 130, Mclean, VA 22101, USA.

Keywords: Germany, Wurzburg, Echinococcosis, Hygiene, University of Wurzburg.

This article was prepared by Life Science Weekly editors from staff and other reports. Copyright 2009, Life Science Weekly via NewsRx.com.

NewsRx NewsRx NewsRx
-----------------------
PR Login